Diabetes Mellitus, Type 2, Vascular Inflammation
Conditions
Keywords
statin, dotatate, vascular inflammation, type 2 diabetes mellitus, pet/ct, positron emmission tomography
Brief summary
To study the effect of atorvastatin treatment on vascular uptake of 68Ga-DOTATATE in patients with Type 2 Diabetes.
Detailed description
Well controlled patients with type 2 diabetes, who are statin naïve, will undergo atorvastatin treatment. Before and after treatment, patients will undergo a 68Ga-DOTATATE PET/CT, to evaluate the effect of treatment on vascular inflammation.
Interventions
Atorvastatin 40mg once daily for three months
Sponsors
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Aged 50 years and older 2. Diagnosed with diabetes mellitus type 2 and using oral glucose lowering therapy, insulin or combined glucose lowering therapy. 3. Not on statin therapy or willing to stop with current statin therapy for 6 weeks prior to visit 2. 4. HbA1c values below 65 mmol/L. 5. Patients with stable diabetes mellitus, i.e. no changes in type of glucose lowering therapy and / or dosage of oral glucose lowering therapy in the past three months. No more than 20% change in dosage of insulin therapy (short and long acting) in the last three months.
Exclusion criteria
1. History of cardiovascular disease (previous CV-event (MI / stroke) or known coronary artery disease (including acute coronary syndrome). 2. History of chronic kidney disease stage 3b - 5, defined as a CKD-EPI value of \< 45 ml/min/1,73m2 3. Malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator. 4. Chronic or recent (\< 1 month) infections and/or clinical signs of acute infection. 5. History of auto-immune diseases. 6. Standard contra-indications to 68Ga-Dotatate PET, and CT based on physicians experience and current practices. 7. Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study. 8. Planned radiation exposure in the next year due to participation in a research project with radiation exposure or for clinical reasons. 9. Elevated liver enzymes (\> 2 ULN of liver transaminases), acute liver failure or known liver disease. 10. Prior medium to severe statin-related side effects or statin related hypersensitivity, i.e. (severe) muscle pains with and/or without myopathy . 11. The concomitant use of statin contra-indicated drugs, including the use of CYP3A4 inhibitors (i.e. erytromycin, dilthiazem, amiodaron, verapamil, fluconazole, ciclosporin, stiripentol, itraconazol, ketoconazol, voriconazol, posaconazol, clarithromycin, ..), systemic use of fusidic acid and ciclosporin. 12. Any contra-indications to the use of statins.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DOTATATE coronary arteries | 3 months | Change in DOTATATE TBRmax coronary arteries after atorvastatin therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in splenic/bone marrow DOTATATE signal | 3 month | The secondary objective of this study is to assess the feasibility to measure splenic and bone-marrow inflammatory activity with 68Ga-Dotatate PET-CT in patients with diabetes mellitus, expressed as SUVmax |
Countries
Netherlands
Outcome results
None listed